Osaic Holdings
GANX icon

Osaic Holdings’s Gain Therapeutics GANX Stock Holding History

Osaic Holdings’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$32.6K – 7272
2023
Q4 		$32.6K Hold
10,000
– – ﹤0.01% 5183
2023
Q3 		$32.8K Hold
10,000
– – ﹤0.01% 5268
2023
Q2 		$44.8K Hold
10,000
– – ﹤0.01% 5009
2023
Q1 		$48.2K Hold
10,000
– – ﹤0.01% 4976
2022
Q4 		$31K Hold
10,000
– – ﹤0.01% 5272
2022
Q3 		$33K Sell
10,000
-100
-1% -$376 ﹤0.01% 5234
2022
Q2 		$36K Buy
10,100
+50
+0.5% +$172 ﹤0.01% 5192
2022
Q1 		$41K Hold
10,050
– – ﹤0.01% 5233
2021
Q4 		$54K Buy
+10,050
New +$69.3K ﹤0.01% 5087

Other funds holding GANX

DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Osaic Holdings's GANX Position: Q1 2024 in Review

Osaic Holdings sold out of Gain Therapeutics (GANX) in Q1 2024, closing a stake of 10,000 shares — an estimated $32.6K sold.

Osaic Holdings first reported a position in GANX in Q4 2021 and held it in 9 quarters. The position peaked at $54K in Q4 2021. 26 funds tracked by Wall St. Rank hold GANX as of Q1 2024.

  • Osaic Holdings reported no remaining Gain Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Osaic Holdings sold 10,000 Gain Therapeutics shares in Q1 2024, an estimated $32.6K.
  • Osaic Holdings first reported a position in Gain Therapeutics in Q4 2021 and held it in 9 quarters.
  • Osaic Holdings's Gain Therapeutics position peaked at $54K in Q4 2021.
  • 26 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2024.

Based on Osaic Holdings's 13F filing for Q1 2024, filed 10 May 2024.